Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know

Host: Matt Birnholz, MD <br> Guest: Gary Cohen, MD <br> <p>What’s the difference between a generic drug and biosimilar? How does the FDA define biosimilarity? And how are biosimilars developed? Get answers to these and other questions with Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC, in the first episode of this two-part video.</p> <p> ©2020 Amgen Inc. All rights reserved. USA-CBU-80726 10/20</p>